Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab

References

• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235(4785)177–82
   PubMed Web of Science ®Google Scholar
• Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16(2)462–9
   PubMedGoogle Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20(3)719–26
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11)783–92
   PubMed Web of Science ®Google Scholar
• Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96(10)759–69
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722–30
   PubMed Web of Science ®Google Scholar
• Fokstuen T, Wilking N, Rutqvist LE, Wolke J, Liedberg A, Signomklao T, et al. Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res Treat 2000; 62(3)211–6
   PubMedGoogle Scholar
• Sparrow GE, Rubens RD. Brain metastases from breast cancer: Clinical course, prognosis and influence of treatment. Clin Oncol 1981; 7(4)291–301
   PubMedGoogle Scholar
• Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991; 49(5)650–5
   PubMedGoogle Scholar
• Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J, et al. Occult central nervous system involvement in patients with metastatic breast cancer: Prevalence, predictive factors and impact on overall survival. Ann Oncol 2003; 14(7)1072–7
   PubMed Web of Science ®Google Scholar
• Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000; 18(11)2349–51
   PubMed Web of Science ®Google Scholar
• Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97(12)2972–7
   PubMed Web of Science ®Google Scholar
• Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91(4)639–43
   PubMed Web of Science ®Google Scholar
• Shmueli E, Wigler N, Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 2004; 40(3)379–82
   PubMedGoogle Scholar
• Lower EE, Drosick DR, Blau R, Brennan L, Danneman W, Hawley DK. Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 2003; 4(2)114–9
   PubMedGoogle Scholar
• Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004; 101(4)810–6
   PubMed Web of Science ®Google Scholar
• Law AJ, Shannon Weickert C, Hyde TM, Kleinman JE, Harrison PJ. Neuregulin-1 (NRG-1) mRNA and protein in the adult human brain. Neuroscience 2004; 127(1)125–36
   PubMedGoogle Scholar
• Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P, et al. Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene 2001; 20(56)8066–74
   PubMedGoogle Scholar
• Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994; 269(20)14661–5
   PubMedGoogle Scholar
• Hernan R, Fasheh R, Calabrese C, Frank AJ, Maclean KH, Allard D, et al. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 2003; 63(1)140–8
   PubMed Web of Science ®Google Scholar
• Kauraniemi P, Barlund M, Monni O, Kallioniemi A. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res 2001; 61(22)8235–40
   PubMedGoogle Scholar
• Han DC, Guan JL. Association of focal adhesion kinase with Grb7 and its role in cell migration. J Biol Chem 1999; 274(34)24425–30
   PubMed Web of Science ®Google Scholar
• Omura GA, Moffitt S, Vogler WR, Salter MM. Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood 1980; 55(2)199–204
   PubMed Web of Science ®Google Scholar
• Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Eng J Med 1999; 341: 476–84
   PubMed Web of Science ®Google Scholar